International News: Spotlight on Foreign Investment

In terms of relative priorities, and therefore opportunities, for investment, the region can broadly be divided into China for biotech innovation; Singapore for Asia Pacific manufacturing, distribution, and R&D; South Korea for manufacturing and biotech development; Japan for pharmaceutical exports; and India for generics and vaccines production.

GOVERNMENT SUPPORT AND REGULATORY REFORMS

Most Asian governments have recognised the importance of the Life Sciences sector as a driver for business growth that also can help them address healthcare policy challenges in their home countries. As a result, it’s likely that there will be a continuation of policies that encourage healthcare innovation. These include expedited drug approval processes, manufacturing incentives, and R&D support. Given the inherent benefits, it can be expected that cross-pollination across universities, bioscience companies, and government-supported funding incubators to monetise innovations will continue.

Government bodies are also actively promoting collaboration with global industry and funding research partners to share healthcare expertise and monetise life sciences IP. While certain markets, such as Singapore, Korea, and Taiwan, have the industry, research, and business infrastructure to drive and export their own life sciences innovations, several others will need continued access to overseas healthcare knowledge, products, and technology. The healthcare regulatory efforts in Asia will continue to be focused on easing the path for international life sciences businesses to access and tap into sustainable revenue streams in these markets.

FOCUS ON BIOTECHNOLOGY AND PRECISION MEDICINE

Biotechnology, including gene therapy, cell therapy, and genomics, has gained significant attention in Asia and there has already been considerable investment in biotechnology R&D. Genomics is a particular focus, given that the genomes of several Asian populations have not yet been fully mapped to develop genomic infrastructures for personalised healthcare for those populations.

Precision medicine tailored to individual genetic makeup, particularly in oncology, will become a major area of focus as these infrastructures are explored, presenting substantial “ground floor” investment opportunities. Asia has already seen a sharp rise in biotech startups focused on developing novel therapies, diagnostics, and technologies in areas such as gene editing, regenerative medicine, and biomarker discovery, and investment is welcomed in the research, diagnostics, and therapeutics fields.

DIGITAL HEALTH AND HEALTHCARE TECHNOLOGY

The rapid advancement of digital technologies has led to a surge in digital health and healthcare technology startups in Asia, all hungry for investment. These startups are leveraging technologies such as artificial intelligence (AI), telemedicine, health monitoring devices, and health data analytics to improve healthcare delivery, medical imaging analysis, diagnostic support, tailored treatment recommendations, patient outcomes, and cost efficiency.

Historical underinvestment in physical healthcare infrastructure, and a highly dispersed and substantially rural population across Asian countries is driving a demand for telemedicine platforms and remote healthcare solutions. There has been a similar surge in mobile health applications that provide health information, track fitness and wellness, and offer remote monitoring capabilities. In conjunction with wearable devices, these offer attractive prospects for accessing large customer datasets for analytics and cross-selling.

IMPACT INVESTING

A trend towards impact investing reflects a broader shift towards responsible investments and the recognition of healthcare’s potential for positive social impact.
Key opportunities for impact investors include healthcare infrastructure, such as clinical facilities and telemedicine platforms, as well as the development and scaling of affordable healthcare solutions in Asia. There is substantial demand for investment in low cost medical devices and generic drugs, as well as funding for digital health startups, healthtech platforms, and AI applications.

A key driver of investing in this space is alignment with the United Nations’ Sustainable Development Goals (SDGs), particularly SDG 3: Good Health and Well-being. Focus outcomes in Asia include reducing maternal and child mortality, combating infectious diseases, and promoting universal healthcare coverage.

INVESTMENT CHALLENGES

Notwithstanding investment growth drivers, there are several challenges for healthcare investments in Asia. Chief among these are regulatory barriers, including restrictions on foreign ownership, licensing requirements, and pricing controls. Foreign ownership restrictions obviously vary from country to country, but in general there is a strong push towards localising bioscience R&D and drug manufacturing. In addition, generating and monetising healthcare data is proving challenging in the face of competing personal data privacy and security considerations.

Intellectual property protection for innovative healthcare technologies and treatments can be relatively weak in some Asian countries. Concerns about protecting and enforcing IP rights remain elevated in markets such as China and India, while others, such as Japan and Singapore, have very well developed regimes.

It is also notable that Asia is a highly diverse and dispersed region, with many different submarkets ranging from advanced and emerging economies. The region is also affected by increased geopolitical instability, making it more challenging to predict the medium to long term profitability of healthcare and life sciences investments, which depend on access to global knowledge, investors, and markets.

Investors need to weigh these considerations carefully in light of their specific objectives and against the overall backdrop of significant growth in the Asian Life Sciences sector, driven by the region’s increasing healthcare demand, government support, focus on biotechnology, digital health advancements, and impact investing trends.

Show Less